AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its…
Consensus price target: $21.98 (+14080.65% upside from $0.16)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Equels Thomas K director, CEO & President | Oct 22, 2026 | Purchase | 31,250 | $5.09K |
| Equels Thomas K director, CEO & President | Sep 17, 2026 | Purchase | 24,000 | $4.99K |
| Equels Thomas K director, CEO & President | Sep 16, 2026 | Purchase | 11,000 | $2.31K |
| Equels Thomas K director, CEO & President | Sep 15, 2026 | Purchase | 22,000 | $4.86K |
| Equels Thomas K director, CEO & President | Sep 14, 2026 | Purchase | 5,900 | $1.29K |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $88K | -48.24% | $-13.96M |
| 2024 | $170K | -15.84% | $-17.32M |
| 2023 | $202K | +43.26% | $-28.96M |
Stock data for AIM: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics